Real-World Safety of Nemolizumab: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System (FAERS) - PubMed
an hour ago
- #Adverse Event Reporting
- #Nemolizumab Safety
- #Pharmacovigilance
- This article analyzes the real-world safety of nemolizumab using data from the FDA Adverse Event Reporting System (FAERS).
- The study focuses on pharmacovigilance, specifically post-marketing safety analysis for conditions like atopic dermatitis and prurigo nodularis.
- It examines and reports on cutaneous adverse reactions and other potential risks associated with nemolizumab treatment.